Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...

The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...

PBGENE-DMD aims to deliver sustained muscle function improvement for DMD patients with mutations between exons 45 and 55.

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued ...

Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...

PowerHome is a manufacturer and global supplier of power conversion equipment, specializing in single-phase and three-phase ...

EPC’s evaluation kit for a three-phase inverter platform based on its Gen-7 EPC2366 eGaN power transistor streamlines motor ...

The Phase 1/2 FUNCTION-DMD study will enroll ambulatory patients and is designed to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes. "The ...

Researchers at Skoltech have developed an ultra-compact electro-optic modulator based on silicon photonics and plasmonics ...

NLM Photonics, a developer of silicon organic hybrid (SOH) photonic solutions, has announced a partnership with photonics ...

Polytec's optical measurement equipment focuses on dynamic response measurements. MEMS devices typically have actively moving ...

A rolling NDA has been initiated for tinlarebant in STGD1, potentially positioning the first disease-modifying systemic ...